{"filing":{"accession_number":"0001079973-26-000997","cik":"0001799191","ticker":"TOIIW","company_name":"Oncology Institute, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-07-28","primary_document":"toi_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000997/toi_8k.htm"},"events":[{"id":23287,"run_id":21057,"accession_number":"0001079973-26-000997","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.8,"summary":"The Oncology Institute, Inc. changed its corporate name to Starling Oncology, Inc. and its ticker symbol from TOI to STLN, effective August 4, 2026, through a Certificate of Amendment filed with Delaware on July 28, 2026. The rebrand is material to investors as it affects the company's public identity and market recognition, though it does not alter the company's operations, assets, or economic substance.","company_name":"Oncology Institute, Inc.","ticker":"TOIIW","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23481,"accession_number":"0001079973-26-000997","item_number":"5.03","item_title":"Amendments to Articles of Incorporation","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This disclosure reports a corporate name change from \"The Oncology Institute, Inc.\" to \"Starling Oncology, Inc.\" effected through a Certificate of Amendment filed with Delaware on July 28, 2026, with a corresponding ticker symbol change from \"TOI\" to \"STLN.\" The filing explicitly states that the name change does not affect stockholder rights and requires no stockholder action. While a name change is a governance matter, it is routine and administrative in nature—the company's operations, assets, liabilities, and economic substance remain unchanged.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:17:21.050812+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23482,"accession_number":"0001079973-26-000997","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Company announced a corporate rebrand from \"The Oncology Institute, Inc.\" to \"Starling Oncology, Inc.\" with a concurrent ticker symbol change from \"TOI\" to \"STLN\" effective August 4, 2026. While a name and ticker change is primarily a governance/administrative matter, it is material to investors as it affects the company's public identity, trading symbol, and market recognition. This does not fit the specific governance categories (auditor, executive appointment/departure, compensation, or shareholder vote), so governance_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:17:21.050812+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23481,"accession_number":"0001079973-26-000997","item_number":"5.03","item_title":"Amendments to Articles of Incorporation","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This disclosure reports a corporate name change from \"The Oncology Institute, Inc.\" to \"Starling Oncology, Inc.\" effected through a Certificate of Amendment filed with Delaware on July 28, 2026, with a corresponding ticker symbol change from \"TOI\" to \"STLN.\" The filing explicitly states that the name change does not affect stockholder rights and requires no stockholder action. While a name change is a governance matter, it is routine and administrative in nature—the company's operations, assets, liabilities, and economic substance remain unchanged.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:17:21.050812+00:00","company_name":"Oncology Institute, Inc.","ticker":"TOIIW","filing_date":"2026-08-03"},{"id":23482,"accession_number":"0001079973-26-000997","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Company announced a corporate rebrand from \"The Oncology Institute, Inc.\" to \"Starling Oncology, Inc.\" with a concurrent ticker symbol change from \"TOI\" to \"STLN\" effective August 4, 2026. While a name and ticker change is primarily a governance/administrative matter, it is material to investors as it affects the company's public identity, trading symbol, and market recognition. This does not fit the specific governance categories (auditor, executive appointment/departure, compensation, or shareholder vote), so governance_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:17:21.050812+00:00","company_name":"Oncology Institute, Inc.","ticker":"TOIIW","filing_date":"2026-08-03"}]}